Modality
Bispecific Ab
MOA
VEGFi
Target
CD38
Pathway
Cell Cycle
MSSMA
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
~Apr 2024
→ ~Jul 2025
Phase 2
Oct 2025
→ Mar 2030
Phase 2Current
NCT03234457
2,425 pts·SMA
2025-10→2030-03·Completed
2,425 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-033.9y awayPh2 Data· SMA
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Complet…
Catalysts
Ph2 Data
2030-03-03 · 3.9y away
SMA
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03234457 | Phase 2 | SMA | Completed | 2425 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK |